Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abnormally, ACA, age, AMG, Amgen, androgen, API, arbitrage, ASC, aspect, bankruptcy, Bayer, bendamustine, BMS, boxed, BRAF, BRAFi, cabazitaxel, capsule, carcinogenicity, caution, chain, clarity, CMC, COMET, COMETRIQ, commensurate, commonly, complaint, complicate, complicating, constitutionality, contrast, converge, correctly, count, coupon, decentralized, defraud, destroyed, dictate, Diplomat, disadvantage, disproportional, disputed, disuse, domestic, enjoy, enzalutamide, erythrodysesthesia, escalation, escrow, ESMO, evidenced, Fargo, feature, flat, forfeited, formulary, foundation, franchise, fraudulent, fulfillment, Fundamental, gastrointestinal, gradual, gradually, greatly, heard, hemorrhage, HIPAA, HITECH, HR, imprisonment, incumbent, indenture, indirectly, infrastructure, ingredient, intent, interruption, inventory, investee, IRRC, Janssen, jaw, judge, judged, knowingly, lapatinib, leukoencephalopathy, MAA, mail, main, malignant, masked, Media, Medivation, microenvironment, MMA, MTC, multicenter, municipal, mutagenicity, myeloid, niche, nonmonetary, North, ocular, onartuzumab, outsourced, outsourcing, pathologic, payor, pediatric, perception, pertinent, PFS, ph, pharmacy, physician, Portability, posterior, postmarketing, presence, privacy, prolongation, promulgation, proteinuria, proton, prudent, pump, quantitative, quickly, radiology, RECIST, reclassification, reclassify, redeem, redeemed, redemption, referral, refractory, reliance, remuneration, repeal, repurchase, repurchased, residual, rituximab, safer, sarcoma, scale, scaled, scheme, shipping, soliciting, sorafenib, sourced, specialty, spread, stepwise, stratified, strong, subordinated, substantive, Subtopic, sunitinib, surrender, takeover, teratogenicity, thousand, thrombotic, tort, trustee, underestimate, underwritten, uninsured, unresectable, unrestricted, unspecified, untreated, unwilling, upheld, vemurafenib, vigorously, violate, violation, warehousing, wholesale, willfully, worsen, wound
Removed:
alan, allocate, andFRANK, announced, assigned, ASU, autoimmune, beneficiary, Boehringer, book, BUCHER, carl, central, certification, cessation, cliff, Cohen, coincide, compensatory, concentration, concluding, confirming, congressional, consolidate, declining, deconsolidated, deducted, depressed, derecognized, dividend, drawn, duly, durable, earliest, encompassing, Esq, exert, exhibit, fall, family, FASB, feldbaum, Frank, garber, Gisela, granting, greatest, GSK, guaranteed, half, Heller, hereof, holding, hurt, inapplicable, incorporation, Ingelheim, invest, irrespective, jack, jurisdiction, karbe, Lance, language, lawful, listed, longest, Marchesi, McCormick, mediator, michael, molecular, morrissey, noncontrolling, omitted, ordering, Pamela, papillary, passed, Portland, Poste, prospectively, ratifying, receivable, reconsideration, recording, reimportation, relationship, replacement, requested, resubstitution, reviewing, Schwab, SEI, separated, sharing, shortage, shutdown, signature, Similarly, Simonton, stead, substitute, Symposium, thereto, thereunto, therewith, thing, true, undersigned, unobservable, vascularization, Vincent, virtue, Willsey, wyszomierski
Filing tables
Filing exhibits
- 10-K Annual report
- 10.6 2000 Non-employee Directors' Stock Option Plan
- 10.25 Compensation Information for Non-employee Directors
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification Required by Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification Required by Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certification by the CEO and CFO As Required by Rule 13A-14(B) or 15D-14(B)
Related press release
EXEL similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-176674, 333-157825, 333-159280, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026, 333-54868, 333-52434, 333-35862, 333-133237, 333-147063 and 333-149834, 333-165389) of Exelixis, Inc. and the Registration Statements on Form S-3 (Nos. 333-182018 and 333-152166) of Exelixis, Inc. of our reports dated February 21, 2013, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended December 28, 2012.
/s/ Ernst & Young LLP
Redwood City, California
February 21, 2013